Synthetic Pineal Tetrapeptide (AEDG, Bioregulator Class — Mitochondrial / Longevity Research) Limited Human Data

Epitalon

Also Known As: Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly, AEDG peptide

Epitalon (also spelled Epithalon; Ala-Glu-Asp-Gly, AEDG) is a synthetic tetrapeptide modeled on the active fraction of Epithalamin — a bovine pineal polypeptide extract developed at the St. Petersburg Institute of Bioregulation and Gerontology from the 1970s. Epithalamin (the natural pineal extract) and Epitalon (the synthetic AEDG tetrapeptide modeled on its active fraction) are not the same substance: the secondary literature routinely conflates the two, including the Korkushko 2004 melatonin paper, which actually used Epithalamin and not synthetic Epitalon. The seminal in vitro telomerase findings in human fetal fibroblasts (Khavinson 2003, PMID 12937682) were independently replicated in vitro by a Brunel University London / Royal Brompton group in 2025 (Al-Dulaimi 2025, PMID 40908429), which additionally observed telomere extension via the ALT (Alternative Lengthening of Telomeres) pathway in breast-cancer cell lines — a translational safety caveat. Epitalon is NOT approved by the FDA, EMA, or any other Western regulatory agency for any clinical indication; a ClinicalTrials.gov v2 API query on 1 May 2026 returned zero hits for "epitalon" or "epithalon". Russian pharmaceutical registration of pineal peptide bioregulators has been reported since the early 1990s but could not be independently verified from primary Russian-language registry documents in this research pass. Anti-aging lifestyle marketing claims are not validated by Triscience editorial.

Identity & Chemistry

Skeletal chemical structure of Epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid and glycine residues.
Image credit: DMacks, via Wikimedia Commons · Public Domain
Amino Acid Sequence
H-Ala-Glu-Asp-Gly-OH (AEDG, 4 amino acids)
Molecular Formula
C₁₄H₂₂N₄O₉
Molecular Weight
390.35 g·mol⁻¹ (≈ 390.4 Da, free acid; PubChem CID 219042)
CAS Number
307297-39-8
PubChem CID
219042
IUPAC Name
(4S)-4-{[(2S)-2-aminopropanoyl]amino}-5-{[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino}-5-oxopentanoic acid
Solubility
Water-soluble; AEDG is a hydrophilic short tetrapeptide and is typically reconstituted with bacteriostatic water or sterile isotonic saline in published studies. Quantitative aqueous solubility data are not publicly disclosed at PubChem CID 219042.
Storage
Lyophilised peptide: store at −20 °C protected from light (long-term). Reconstituted solutions: store at 2–8 °C, short-term. Vendor / supplier certificate of analysis governs; for research use only.

Mechanism of Action

Epitalon (AEDG) is hypothesised to act as a peptide bioregulator that activates telomerase (TERT) in somatic cells in vitro and to modulate pineal melatonin output, with secondary epigenetic effects proposed via direct binding to linker histones H1/3 and H1/6 and selective gene-expression activation. Systemic telomerase activation in living humans has not been demonstrated in peer-reviewed literature.

The mechanistic literature on Epitalon is largely inferred from in vitro fibroblast experiments and rodent studies and is NOT validated by clinical-grade pharmacokinetic or target-engagement data in humans. Studies report that the seminal Khavinson 2003 paper (Bull Exp Biol Med, PMID 12937682) added Epithalon directly to telomerase-negative human fetal fibroblast cultures and observed re-expression of the catalytic TERT subunit, telomerase activity, and continued cell division beyond the Hayflick limit (passage 44+ vs. control halt at passage 34) — an in vitro finding, NOT evidence of human in vivo telomerase reactivation. The 2025 independent in vitro study from Brunel University London / Royal Brompton confirmed dose-dependent telomere extension in normal fibroblasts and epithelial cells via hTERT upregulation, while observing ALT-pathway lengthening in breast-cancer cell lines — the first clearly non-Khavinson-affiliated replication of the core telomere finding, with a concurrent safety flag (Al-Dulaimi 2025, PMID 40908429). The 2025 Polish review by Araj et al. (Int J Mol Sci, PMID 40141333) explicitly concludes that "it remains uncertain whether these are the sole mechanisms of action" and that "information regarding critical issues about this peptide's safety is missing". No peer-reviewed human pharmacodynamic study has demonstrated systemic telomerase activation in vivo from peripheral Epitalon administration. Mechanism statements here are therefore intentionally hedged — studies report, proposed pathways, observed in vitro — and never framed as established human pharmacology. Anti-aging marketing that promotes Epitalon as a human telomerase activator overstates what the published evidence actually shows.

Molecular Targets

  • Telomerase / hTERT (human somatic cells, in vitro) — induction of hTERT mRNA expression and telomerase enzymatic activity in telomerase-negative human fetal fibroblasts (Khavinson 2003); independently replicated in vitro in normal fibroblasts and epithelial cells in 2025 (Al-Dulaimi 2025)
  • ALT pathway (Alternative Lengthening of Telomeres) — in breast-cancer cell lines (21NT, BT474), telomere extension proceeded via the ALT pathway rather than telomerase upregulation; ALT is associated with more aggressive tumor phenotypes (Al-Dulaimi 2025)
  • Linker histones H1/3 and H1/6 (proposed) — molecular docking and cell-culture data in human gingival mesenchymal stem cells suggest binding to linker histones and derepression of neurogenic differentiation markers (Nestin, GAP43, β-Tubulin III, Doublecortin) by ~1.6–1.8× (Khavinson 2020)
  • Pineal axis / melatonin (proposed) — restoration of nocturnal melatonin secretion in subjects with diminished pineal function; evidence is largely from studies that used Epithalamin (the natural extract), NOT synthetic Epitalon (Korkushko 2004)

Signaling Pathways

  • Putative hTERT upregulation in normal somatic cells (in vitro) → telomere extension via the canonical telomerase axis (Khavinson 2003; Al-Dulaimi 2025)
  • In cancer cell lines, telomere extension via the ALT pathway rather than telomerase — translational safety caveat in the independent replication (Al-Dulaimi 2025)
  • Proposed linker-histone-mediated derepression of neurogenic markers (Nestin, GAP43, β-Tubulin III, Doublecortin) in hGMSCs (Khavinson 2020)
  • Proposed modulation of the pineal-melatonin axis — evidence base largely from Epithalamin studies (Korkushko 2004); a separate small Khavinson series with synthetic Epitalon reports a ~1.6× increase in melatonin excretion vs. placebo

Research Applications

The published evidence base consists of in vitro fibroblast and epithelial-cell studies, an SHR-mouse lifespan study, a small open-label retinitis-pigmentosa pilot, and observations of the pineal-melatonin axis — some of which used the pineal extract Epithalamin rather than synthetic Epitalon. Six of the eight primary peer-reviewed references are authored by the Khavinson group at the St. Petersburg Institute; clearly independent replications are limited to the Al-Dulaimi 2025 in vitro study and the Polish review by Araj 2025.

Telomerase activation / telomere length — human fetal fibroblasts, in vitro

in vitro

Studies report that in telomerase-negative human fetal fibroblasts, Epithalon induced re-expression of the hTERT subunit, measurable telomerase activity, and continued cell division beyond the Hayflick limit (passage 44+ vs. control ~passage 34). In 2025 this finding was independently confirmed in IBR.3 fibroblasts and HMEC epithelial cells from Brunel University London — but in the 21NT and BT474 breast-cancer lines, telomere extension proceeded via the ALT pathway rather than telomerase, framed as a translational safety flag.

— Khavinson et al. 2003, Bull Exp Biol Med 135(6):590-592 (PMID 12937682); Al-Dulaimi et al. 2025, Biogerontology (PMID 40908429)

Lifespan and aging biomarkers — SHR mice, in vivo (n = 54/group)

in vivo

Studies report under 1.0 µg/mouse subcutaneous, 5 days/month from age 3 months until natural death: no change in mean lifespan; maximum lifespan +12.3%; survival of last 10% +13.3%; bone-marrow chromosomal aberrations −17.1%; spontaneous-leukemia incidence 6.0× lower than controls; total tumor incidence unchanged. Observed in research settings; translation to human lifespan is not established.

— Anisimov et al. 2003, Biogerontology 4(4):193–202 (PMID 14501183)

Retinitis pigmentosa — Campbell rat and small open-label human pilot

observational

Studies report in Campbell rats (hereditary RP model) preservation of retinal morphology and bioelectric activity under Epitalon. A follow-on pilot at the St. Petersburg Institute describes a "positive clinical effect" in approximately 90% of treated patients with degenerative retinal lesions, mean visual-acuity improvement of 0.15–0.20, and visual-field expansion of 90–120° in 64.8% of patients. Editorial caveat: small single-center open-label observational study, no blinded control arm; no Western RCT replication.

— Khavinson et al. 2002, Neuro Endocrinol Lett 23(4):365–368 (PMID 12195242); summarised in Araj et al. 2025

Pineal / circadian function — older adults (NOTE: largely Epithalamin data, not Epitalon)

observational

Studies report under the bovine pineal extract Epithalamin in older subjects with reduced pineal function an increase in nocturnal plasma melatonin; in subjects with normal baseline function, melatonin tended to decrease — interpreted as a normalising effect. IMPORTANT DISTINCTION: this trial used EPITHALAMIN (the natural pineal extract), NOT synthetic AEDG Epitalon. A separate small Khavinson series (n ≈ 75 women) reports a ~1.6× increase in melatonin excretion vs. placebo with synthetic Epitalon.

— Korkushko et al. 2004, Bull Exp Biol Med 137(4):389–391 (PMID 15452611) — trial used Epithalamin, NOT Epitalon

Neurogenic gene expression / epigenetics — human gingival mesenchymal stem cells, in vitro

in vitro

Studies report that in human gingival mesenchymal stem cells under AEDG/Epitalon, mRNA levels of Nestin, GAP43, β-Tubulin III and Doublecortin increased 1.6–1.8-fold; molecular docking suggests binding to linker histones H1/3 and H1/6 as a candidate epigenetic mechanism.

— Khavinson et al. 2020, Molecules 25(3):609 (PMID 32019204)

Clinical Status

Regulatory Status
Epitalon is NOT approved by any Western regulatory agency — neither the FDA, EMA, MHRA, TGA nor Health Canada — for any clinical indication. A systematic ClinicalTrials.gov v2 API query on 1 May 2026 for "epitalon" and "epithalon" returned zero active or completed Western-registered trials (zero ClinicalTrials.gov NCT IDs, queried 2026-05-01). Registration of related pineal peptide bioregulators in the USSR/Russia from the 1980s (Epithalamin extract) and from approximately 1990 (AEDG class) for geriatric indications is reported in the Khavinson review literature; primary Russian-language pharmaceutical registry documents could not be independently verified in this research pass — flagged as "reported, not independently verified". Anti-aging lifestyle marketing claims are not validated by Triscience editorial.
Show more
Highest Trial Phase
Highest published phase: small open-label human pilot studies and observational case series from a single center (St. Petersburg Institute of Bioregulation and Gerontology); NO Western Phase 1/2/3 RCTs.
Sponsor
St. Petersburg Institute of Bioregulation and Gerontology, North-Western Branch of the Russian Academy of Medical Sciences; principal investigator: Vladimir Kh. Khavinson. There is no Western marketing-authorisation holder; the substance is exclusively investigational.
Show more

Safety Profile

Observed in research settings

Studies report no measurable changes in food consumption, body weight, or total tumor incidence in a chronic SHR-mouse lifespan study. Human safety data are limited to small open-label studies (typically tens of patients) from the Khavinson group with no independent long-term pharmacovigilance dataset; the 2025 Polish review by Araj explicitly concludes that "information regarding critical issues about this peptide's safety is missing" and calls for short- and long-term toxicity, genotoxicity, and carcinogenicity studies before any pharmaceutical-ingredient designation. Observed in research settings.

Adverse Events Reported in Studies

  • No clustered treatment-related adverse events reported in the published Anisimov 2003 SHR-mouse toxicology (chronic monthly dosing, life-long)
  • No systematically captured adverse events from the small open-label Khavinson human studies (intramuscular or intranasal); sample sizes typically small, follow-up short
  • Local injection-site reactions with subcutaneous / intramuscular administration are biologically plausible but have not been systematically documented in the primary literature

Serious Adverse Events

  • Theoretical oncologic concern: telomerase reactivation in somatic cells is a recognised theoretical carcinogenicity concern. The independent 2025 Brunel replication showed that some cancer cell lines respond via the ALT pathway — ALT-positive tumors are associated with more aggressive phenotypes (Al-Dulaimi 2025)
  • Human data gap: NO independent long-term human pharmacovigilance dataset for Epitalon exists — safety statements should be tagged exclusively as "observed in research settings" or "in small open-label studies"
  • Editorial safety flag: the 2025 Polish review by Araj concludes that "information regarding critical issues about this peptide's safety is missing" and calls for short- and long-term toxicity, genotoxicity, and carcinogenicity studies before any pharmaceutical-ingredient designation

References

  1. Khavinson VKh, Bondarev IE, Butyugov AA Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Bull Exp Biol Med 2003;135(6):590–592. 2003 .

    DOI: 10.1023/A:1025493705728 PMID: 12937682 View Source

  2. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice Biogerontology 2003;4(4):193–202. 2003 .

    DOI: 10.1023/A:1025114230714 PMID: 14501183 View Source

  3. Khavinson VKh, Razumovsky MI, Trofimova S, Grigorian R, Razumovskaya AM Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa Neuro Endocrinol Lett 2002;23(4):365–368. 2002 .

    PMID: 12195242 View Source

  4. Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people Bull Exp Biol Med 2004;137(4):389–391. 2004 .

    DOI: 10.1023/B:BEBM.0000035139.31138.bf PMID: 15452611 View Source

  5. Khavinson VKh, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism Molecules 2020;25(3):609. 2020 .

    DOI: 10.3390/molecules25030609 PMID: 32019204 View Source

  6. Khavinson VKh Peptides and Ageing Neuro Endocrinol Lett 2002;23 Suppl 3:11–144. 2002 .

    PMID: 12374906 View Source

  7. Al-Dulaimi S, Matta S, Roberts T, Thomas R Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity Biogerontology 2025. 2025 .

    DOI: 10.1007/s10522-025-10315-x PMID: 40908429 View Source

  8. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties Int J Mol Sci 2025;26(6):2691. 2025 .

    DOI: 10.3390/ijms26062691 PMID: 40141333 View Source

Frequently Asked Questions

Are Epitalon and Epithalamin the same molecule?
No. Epithalamin is a bovine pineal polypeptide EXTRACT developed in the Soviet Union from the 1970s. Epitalon (also spelled Epithalon) is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), modeled on the active fraction of Epithalamin. Several frequently cited "Epitalon" human studies — including the Korkushko 2004 melatonin paper — actually used Epithalamin and not the synthetic peptide.
Does Epitalon activate telomerase in humans?
Telomerase activation has been demonstrated in vitro in human fetal fibroblasts (Khavinson 2003, PMID 12937682) and replicated in vitro by an independent Brunel University London group in normal fibroblasts and epithelial cells in 2025 (Al-Dulaimi 2025, PMID 40908429). There is NO peer-reviewed evidence of systemic telomerase reactivation in living humans from peripheral administration. The "telomerase activator in humans" framing common in marketing material overstates what the published evidence shows.
Is Epitalon FDA approved?
No. Epitalon is NOT approved by the FDA, the EMA, or any other Western regulatory agency for any clinical indication. It is sold in the US and EU strictly as a research chemical. A ClinicalTrials.gov v2 API query on 1 May 2026 returned zero registered Epitalon trials (zero ClinicalTrials.gov NCT IDs, queried 2026-05-01). Reports of Russian pharmaceutical registration exist in the Khavinson review literature but were not independently verified from primary Russian-language registry documents in this research pass.
What is AEDG?
AEDG is the single-letter amino-acid abbreviation for Ala-Glu-Asp-Gly — the four-residue sequence of Epitalon. The forms "AEDG peptide" and "Epitalon" refer to the same molecule (PubChem CID 219042, CAS 307297-39-8, formula C₁₄H₂₂N₄O₉, molecular mass 390.35 Da).
What is the evidence base for Epitalon?
Roughly two decades of preclinical and small-clinical work — the majority authored by a single research group (Khavinson, St. Petersburg Institute of Bioregulation and Gerontology) and published in Russian-published English-language journals such as Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters. Six of the eight primary references are from this group; clearly independent replication outside this lineage is limited but emerging (Al-Dulaimi 2025, Brunel University London). No Western Phase 1/2/3 randomised clinical trial has been completed.
Are the "anti-aging" claims for Epitalon validated?
No. Lifespan-extension findings are limited to rodents (with mean lifespan unchanged and only maximum lifespan extended in the SHR-mouse study) and to in vitro cellular senescence. Long-term human longevity outcomes have not been studied. Anti-aging marketing claims circulating in non-peer-reviewed channels are NOT validated by Triscience editorial.

Related Peptides

Thymosin Alpha-1

≥98%

Thymic peptide hormone analogue / immune modulator (slug: immune-other; pleiotropic TLR2/TLR9-mediated effect rather than a classical single-receptor agonist)

Synthetic 28-amino-acid N-acetylated thymic peptide (thymalfasin / Zadaxin); pleiotropic TLR2/TLR9-mediated immune modulator — approved as Zadaxin in 35+ countries (Italy, China, Vietnam, Mexico and others) for chronic hepatitis B and as a vaccine adjuvant in immunocompromised populations, but NOT FDA-approved in the United States — only orphan-drug designations exist there.

View Details

GHK-Cu

≥98%

Endogenous Cu(II)-binding tripeptide (cosmetic ingredient / skin-regeneration research)

Endogenous tripeptide glycyl-L-histidyl-L-lysine (GHK) that avidly chelates Cu(II); INCI-listed cosmetic ingredient "Copper Tripeptide-1", not an FDA-approved drug. Studied for skin remodeling, wound healing, and gene-expression modulation; for research use only.

View Details

Sermorelin

≥98%

GHRH(1-29) Receptor Agonist (Growth-Hormone Secretagogue, GRF Class)

Synthetic GHRH(1-29) amide (Geref); the shortest fragment of human growth-hormone-releasing hormone that retains full biological activity — historically FDA-approved for pediatric GH deficiency and voluntarily withdrawn from the US market in 2008 for commercial reasons.

View Details